NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

Expression of NPRL2/TUSC4, a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1R/KRAS/STK11mt NSCLC in humanized-mice. Humanized-mice were generated by...

Full description

Saved in:
Bibliographic Details
Main Authors: Ismail M Meraz, Mourad Majidi, Renduo Song, Feng Meng, Lihui Gao, Qi Wang, Jing Wang, Elizabeth J Shpall, Jack A Roth
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2025-02-01
Series:eLife
Subjects:
nprl2 gene therapy
NSCLC
anti-PD1 resistance
KRAS/STK11 mutation
humanized mouse model
Online Access:https://elifesciences.org/articles/98258
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://elifesciences.org/articles/98258

Similar Items